Intradigm’s lead product candidate ICS-283 is a nanoparticle-based siRNA targeting the VEGF (Vascular Endothelial Growth Factor) pathway. The product uses an RGD peptide as the ligand to target av-expressing endothelial cells. ICS-283 is currently in the preclinical stage. Data from several in vivo models including xenograft models of different cancers (colorectal, renal, head and neck, and breast) have confirmed an RNAi-mediated anti-angiogenic effect following systemic administration similar to VEGF antibody. VEGF, as a validated target in the treatment of cancer, provides a clear clinical development path to validate the success of Intradigm systemic delivery of RNAi in man.


Date Type Amount Investors Valuation
11/21/06 Series A 16M Alta Partners, Emerging Technology Partners, Frazier Healthcare Ventures, Genentech, MediBic Alliance/Daiichi, Novartis Ventures Unknown
01/01/09 Series B 21.4M Lilly Ventures, MP Healthcare Venture Management, Frazier Healthcare Ventures, Alta Partners, MediBic Alliance Technology Fund, Novartis Venture Fund, Astellas Venture Management Unknown


Samuel Zalipsky (VP Technology Development)

Martin Woodle (Chief Scientific Officer)

Xiao-Dong Yang (VP Research & Preclinical Development)

Wei-Wu He (Board Member)

View more details about all 11 people at Intradigm